Galecto Stock Today
| GLTO Stock | USD 34.14 4.65 15.77% |
PerformanceGood
| Odds Of DistressAverage
|
Galecto is selling at 34.14 as of the 28th of December 2025; that is 15.77 percent increase since the beginning of the trading day. The stock's open price was 29.49. Galecto has over 55 % chance of experiencing financial distress in the next 2 years of operation, but had a somewhat good returns during the last 90 days. The performance scores are derived for the period starting the 28th of November 2025 and ending today, the 28th of December 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of October 2020 | Category Healthcare | Classification Health Care |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts. Galecto operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.59 M outstanding shares of which 181.09 K shares are currently shorted by private and institutional investors with about 0.12 trading days to cover. More on Galecto
Moving together with Galecto Stock
Moving against Galecto Stock
Galecto Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsGalecto can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Galecto's financial leverage. It provides some insight into what part of Galecto's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Galecto (GLTO) is traded on NASDAQ Exchange in USA and employs 5 people. Galecto is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 43.73 M. Galecto conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.59 M outstanding shares of which 181.09 K shares are currently shorted by private and institutional investors with about 0.12 trading days to cover.
Galecto currently holds about 79.03 M in cash with (18.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.11.
Check Galecto Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Galecto is $43.73 Million. Galecto retains 3.56 (percent) of its outstanding shares held by insiders and 13.38 (percent) owned by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Galecto Ownership Details
Galecto Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jpmorgan Chase & Co | 2025-03-31 | 0.0 | |
| Squarepoint Ops Llc | 2025-06-30 | 0.0 | |
| Novo A/s | 2025-06-30 | 99.9 K | |
| Renaissance Technologies Corp | 2025-06-30 | 14.5 K | |
| Susquehanna International Group, Llp | 2025-06-30 | 13.6 K | |
| Ubs Group Ag | 2025-06-30 | 2.3 K | |
| Bank Of America Corp | 2025-06-30 | 1.2 K | |
| Tower Research Capital Llc | 2025-06-30 | 942 | |
| Blackrock Inc | 2025-06-30 | 100.0 | |
| Barclays Plc | 2025-06-30 | 100.0 | |
| Sbi Securities Co Ltd | 2025-06-30 | 18.0 |
Galecto Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Galecto market risk premium is the additional return an investor will receive from holding Galecto long position in a well-diversified portfolio.
| Mean Deviation | 21.4 | |||
| Semi Deviation | 8.35 | |||
| Standard Deviation | 57.05 | |||
| Variance | 3255.15 |
Galecto Stock Against Markets
Galecto Corporate Management
| Garrett Esq | General VP | Profile | |
| CPA CPA | Chief Officer | Profile | |
| Ulf Nilsson | CoFounder | Profile | |
| Hakon Leffler | CoFounder | Profile | |
| Lori Firmani | Interim Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galecto. If investors know Galecto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galecto listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Galecto is measured differently than its book value, which is the value of Galecto that is recorded on the company's balance sheet. Investors also form their own opinion of Galecto's value that differs from its market value or its book value, called intrinsic value, which is Galecto's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galecto's market value can be influenced by many factors that don't directly affect Galecto's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galecto's value and its price as these two are different measures arrived at by different means. Investors typically determine if Galecto is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galecto's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.